CN102559657A - 两片段连接法进行hbv全基因组克隆的方法 - Google Patents
两片段连接法进行hbv全基因组克隆的方法 Download PDFInfo
- Publication number
- CN102559657A CN102559657A CN2011103533822A CN201110353382A CN102559657A CN 102559657 A CN102559657 A CN 102559657A CN 2011103533822 A CN2011103533822 A CN 2011103533822A CN 201110353382 A CN201110353382 A CN 201110353382A CN 102559657 A CN102559657 A CN 102559657A
- Authority
- CN
- China
- Prior art keywords
- hbv
- seq
- district
- psx
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000012634 fragment Substances 0.000 title claims abstract description 27
- 241000700721 Hepatitis B virus Species 0.000 title abstract description 10
- 238000010367 cloning Methods 0.000 title abstract description 6
- 108020004414 DNA Proteins 0.000 claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 230000003321 amplification Effects 0.000 claims description 18
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 102000012410 DNA Ligases Human genes 0.000 claims description 3
- 108010061982 DNA Ligases Proteins 0.000 claims description 3
- 108010042407 Endonucleases Proteins 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims description 2
- 238000007857 nested PCR Methods 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 abstract 3
- 102000053602 DNA Human genes 0.000 abstract 2
- 238000001976 enzyme digestion Methods 0.000 abstract 2
- 239000000047 product Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 230000004087 circulation Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000013412 genome amplification Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103533822A CN102559657A (zh) | 2011-11-09 | 2011-11-09 | 两片段连接法进行hbv全基因组克隆的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103533822A CN102559657A (zh) | 2011-11-09 | 2011-11-09 | 两片段连接法进行hbv全基因组克隆的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102559657A true CN102559657A (zh) | 2012-07-11 |
Family
ID=46406264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103533822A Pending CN102559657A (zh) | 2011-11-09 | 2011-11-09 | 两片段连接法进行hbv全基因组克隆的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102559657A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103282497A (zh) * | 2010-08-17 | 2013-09-04 | 默沙东公司 | 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制 |
US10513703B2 (en) | 2014-11-10 | 2019-12-24 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
US11492623B2 (en) | 2018-08-13 | 2022-11-08 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101948827A (zh) * | 2010-08-19 | 2011-01-19 | 中国人民解放军第三〇二医院 | 一种低载量乙型肝炎病毒全基因组克隆的方法 |
-
2011
- 2011-11-09 CN CN2011103533822A patent/CN102559657A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101948827A (zh) * | 2010-08-19 | 2011-01-19 | 中国人民解放军第三〇二医院 | 一种低载量乙型肝炎病毒全基因组克隆的方法 |
Non-Patent Citations (1)
Title |
---|
张天英等: "高灵敏度巢式PCR方法扩增HBV全长基因组", 《厦门大学学报(自然科学版)》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103282497A (zh) * | 2010-08-17 | 2013-09-04 | 默沙东公司 | 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制 |
CN103282497B (zh) * | 2010-08-17 | 2018-07-10 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制 |
US10513703B2 (en) | 2014-11-10 | 2019-12-24 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
US11060091B2 (en) | 2014-11-10 | 2021-07-13 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
US11492623B2 (en) | 2018-08-13 | 2022-11-08 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
US12173289B2 (en) | 2018-08-13 | 2024-12-24 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vojtechova et al. | The role of miRNAs in virus-mediated oncogenesis | |
Feederle et al. | The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes | |
CN107502608B (zh) | 用于敲除人ALDH2基因的sgRNA、ALDH2基因缺失细胞株的构建方法及应用 | |
Pyrc et al. | Identification of new human coronaviruses | |
Bernard et al. | Novel HIV-1 miRNAs stimulate TNFα release in human macrophages via TLR8 signaling pathway | |
Forte et al. | The role of microRNAs in Epstein-Barr virus latency and lytic reactivation | |
Nagel et al. | Varicella-zoster virus transcriptome in latently infected human ganglia | |
Zhou et al. | Influenza A virus molecular virology techniques | |
Lin et al. | Small RNA profiling reveals antisense transcription throughout the KSHV genome and novel small RNAs | |
Robles-Sikisaka et al. | Evidence of recombination and positive selection in cetacean papillomaviruses | |
Ilouze et al. | Coordinated and sequential transcription of the cyprinid herpesvirus-3 annotated genes | |
CN102559657A (zh) | 两片段连接法进行hbv全基因组克隆的方法 | |
CN101935710B (zh) | 一种鸽性别鉴别方法 | |
Cuevas et al. | Human norovirus hyper-mutation revealed by ultra-deep sequencing | |
CN101948827A (zh) | 一种低载量乙型肝炎病毒全基因组克隆的方法 | |
CN106867967A (zh) | Midkine稳定低表达的LM3细胞系及其构建方法 | |
CN103820574B (zh) | 人疱疹病毒6型实时荧光定量pcr分型检测试剂盒 | |
CN104745551A (zh) | 利用talen敲除人乳头瘤病毒e6e7癌基因的方法 | |
Avilala et al. | Role of virally encoded circular RNAs in the pathogenicity of human oncogenic viruses | |
Lee et al. | Methods for detection and study of virus-derived small RNAs produced from the intramolecular base-pairing region of the picornavirus genome | |
Ceballos-Garzon et al. | Applying targeted gene hybridization capture to viruses with a focus to SARS-CoV-2 | |
CN101638691B (zh) | 用于核酸pcr产物直接测序的测序引物和测序方法 | |
CN103305477A (zh) | 痘苗病毒的gfp示踪系统及其应用 | |
Song et al. | High-throughput sequencing of putative novel microRNAs in rhesus monkey peripheral blood mononuclear cells following EV71 and CA16 infection | |
CN101250552A (zh) | 肿瘤坏死因子α基因的报告质粒与构建方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Dongping Inventor after: Liu Yan Inventor after: Xu Zhihui Inventor after: Wang Yao Inventor after: Li Xiaodong Inventor after: Zhong Yanwei Inventor after: Dai Jiuzeng Inventor after: Wang Lin Inventor before: Xu Dongping Inventor before: Liu Yan Inventor before: Xu Zhihui Inventor before: Wang Yao Inventor before: Li Xiaodong Inventor before: Zhong Yanwei Inventor before: Dai Jiuzeng Inventor before: Wang Lin |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120711 |